Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma.

Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE, Tan KS, Jones DR, Kris MG, Adusumilli PS, Travis WD.

J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33494-4. doi: 10.1016/j.jtho.2018.11.017. [Epub ahead of print]

PMID:
30503889
2.

Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance.

Takahashi Y, Eguchi T, Kameda K, Lu S, Vaghjiani RG, Tan KS, Travis WD, Jones DR, Adusumilli PS.

Oncotarget. 2018 Nov 6;9(87):35742-35751. doi: 10.18632/oncotarget.26285. eCollection 2018 Nov 6.

3.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.

Brandt WS, Yan W, Zhou J, Tan KS, Montecalvo J, Park BJ, Adusumilli PS, Huang J, Bott MJ, Rusch VW, Molena D, Travis WD, Kris MG, Chaft JE, Jones DR.

J Thorac Cardiovasc Surg. 2018 Oct 10. pii: S0022-5223(18)32606-0. doi: 10.1016/j.jtcvs.2018.09.098. [Epub ahead of print]

PMID:
30415902
4.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
5.

Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis.

Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, Chou TY, Dienemann H, Muley T, Nakajima J, Shinozaki-Ushiku A, Wu YC, Lu S, Kadota K, Jones DR, Travis WD, Tan KS, Adusumilli PS.

J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33119-8. doi: 10.1016/j.jtho.2018.09.008. [Epub ahead of print]

PMID:
30253972
6.

Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Eguchi T, Kameda K, Lu S, Bott MJ, Tan KS, Montecalvo J, Chang JC, Rekhtman N, Jones DR, Travis WD, Adusumilli PS.

J Thorac Oncol. 2018 Sep 19. pii: S1556-0864(18)33115-0. doi: 10.1016/j.jtho.2018.09.005. [Epub ahead of print]

PMID:
30244070
7.

Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma.

Kameda K, Eguchi T, Lu S, Qu Y, Tan KS, Kadota K, Adusumilli PS, Travis WD.

J Thorac Oncol. 2018 Dec;13(12):1919-1929. doi: 10.1016/j.jtho.2018.08.2022. Epub 2018 Sep 7.

PMID:
30195703
8.

Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.

Brandt WS, Yan W, Leeman JE, Tan KS, Park BJ, Adusumilli PS, Bott MJ, Molena D, Isbell J, Chaft J, Rimner A, Jones DR.

Ann Thorac Surg. 2018 Sep;106(3):848-855. doi: 10.1016/j.athoracsur.2018.04.064. Epub 2018 May 26.

PMID:
29807005
9.

Minimally Invasive Lobectomy Is Associated With Lower Noncancer-specific Mortality in Elderly Patients: A Propensity Score Matched Competing Risks Analysis.

Hristov B, Eguchi T, Bains S, Dycoco J, Tan KS, Isbell JM, Park BJ, Jones DR, Adusumilli PS.

Ann Surg. 2018 Apr 18. doi: 10.1097/SLA.0000000000002772. [Epub ahead of print]

PMID:
29672399
10.

What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?

Aherne EA, Plodkowski AJ, Montecalvo J, Hayan S, Zheng J, Capanu M, Adusumilli PS, Travis WD, Ginsberg MS.

Lung Cancer. 2018 Apr;118:83-89. doi: 10.1016/j.lungcan.2018.01.013. Epub 2018 Feb 3.

PMID:
29572008
11.

Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS.

Curr Opin Immunol. 2018 Apr;51:103-110. doi: 10.1016/j.coi.2018.03.002. Epub 2018 Mar 16. Review.

PMID:
29554494
12.

Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.

Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS.

Ann Thorac Surg. 2018 Jul;106(1):178-183. doi: 10.1016/j.athoracsur.2018.02.030. Epub 2018 Mar 14.

PMID:
29550207
13.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.

Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2710-2721.e3. doi: 10.1016/j.jtcvs.2018.01.086. Epub 2018 Feb 15.

PMID:
29548582
14.

Competing risks and cancer-specific mortality: why it matters.

Tan KS, Eguchi T, Adusumilli PS.

Oncotarget. 2017 Dec 28;9(7):7272-7273. doi: 10.18632/oncotarget.23729. eCollection 2018 Jan 26. No abstract available.

15.

Tracing the origin, tracking the evolution, and the treatment of the future.

Emoto K, Vaghjiani RG, Adusumilli PS.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1203-1204. doi: 10.1016/j.jtcvs.2017.12.024. Epub 2017 Dec 9. No abstract available.

PMID:
29452466
16.

Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS.

Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.

17.

Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.

Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, Husain AN.

Mod Pathol. 2018 Apr;31(4):598-606. doi: 10.1038/modpathol.2017.170. Epub 2018 Jan 12.

PMID:
29327706
18.

Micropapillary lung adenocarcinoma and micrometastasis.

Qu Y, Aly RG, Takahashi Y, Adusumilli PS.

J Thorac Dis. 2017 Oct;9(10):3443-3446. doi: 10.21037/jtd.2017.09.62. No abstract available.

19.

Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma.

Brandt WS, Bouabdallah I, Tan KS, Park BJ, Adusumilli PS, Molena D, Bains MS, Huang J, Isbell JM, Bott MJ, Jones DR.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1212-1224.e3. doi: 10.1016/j.jtcvs.2017.09.151. Epub 2017 Nov 13.

PMID:
29246549
20.

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS.

J Thorac Oncol. 2018 Jan;13(1):16-26. doi: 10.1016/j.jtho.2017.10.001. Epub 2017 Oct 26. Review. Erratum in: J Thorac Oncol. 2018 Aug;13(8):1229.

PMID:
29107016
21.

New staging system for pulmonary neuroendocrine tumors: A clinical and pathologic necessity.

Lee MC, Aly RG, Adusumilli PS.

J Thorac Cardiovasc Surg. 2018 Jan;155(1):367-368. doi: 10.1016/j.jtcvs.2017.09.068. Epub 2017 Sep 22. No abstract available.

PMID:
29102207
22.

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.

Eguchi T, Kadota K, Mayor M, Zauderer MG, Rimner A, Rusch VW, Travis WD, Sadelain M, Adusumilli PS.

Oncotarget. 2017 Sep 12;8(44):77872-77882. doi: 10.18632/oncotarget.20845. eCollection 2017 Sep 29.

23.

BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.

Bucciarelli PR, Tan KS, Chudgar NP, Brandt W, Montecalvo J, Eguchi T, Liu Y, Aly R, Travis WD, Adusumilli PS, Jones DR.

J Thorac Oncol. 2018 Jan;13(1):73-84. doi: 10.1016/j.jtho.2017.10.006. Epub 2017 Oct 31.

PMID:
29097253
24.

Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?

Chudgar NP, Brennan MF, Tan KS, Munhoz RR, D'Angelo SP, Bains MS, Huang J, Park BJ, Adusumilli PS, Tap WD, Jones DR.

Ann Thorac Surg. 2017 Dec;104(6):1837-1845. doi: 10.1016/j.athoracsur.2017.07.024. Epub 2017 Nov 2.

25.

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.

Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LM.

Clin Cancer Res. 2017 Dec 15;23(24):7483-7489. doi: 10.1158/1078-0432.CCR-17-2169. Epub 2017 Sep 28.

PMID:
28972039
26.

Immunotherapy for Non-Small Cell Lung Cancer: A Therapy for All Stages?

Aly RG, Vaghjiani RG, Adusumilli PS.

Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):416-417. doi: 10.1053/j.semtcvs.2017.08.014. Epub 2017 Aug 24. No abstract available.

PMID:
28967537
27.

The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK.

Amin EM, Liu Y, Deng S, Tan KS, Chudgar N, Mayo MW, Sanchez-Vega F, Adusumilli PS, Schultz N, Jones DR.

Sci Signal. 2017 Sep 19;10(497). pii: eaah3941. doi: 10.1126/scisignal.aah3941.

28.

Preponderance of High-Grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma.

Takahashi Y, Eguchi T, Lu S, Downey RJ, Jones DR, Travis WD, Adusumilli PS.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):816-818. doi: 10.1164/rccm.201705-0924LE. No abstract available.

PMID:
28862875
29.

Erratum to: Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Gao S, Stein S, Petre EN, Shady W, Durack JC, Ridge C, Adusumilli PS, Rekhtman N, Solomon SB, Ziv E.

Cardiovasc Intervent Radiol. 2017 Oct;40(10):1658. doi: 10.1007/s00270-017-1767-1. No abstract available.

PMID:
28799111
30.

Immunotherapy for malignant pleural mesothelioma: current status and future directions.

Dozier J, Zheng H, Adusumilli PS.

Transl Lung Cancer Res. 2017 Jun;6(3):315-324. doi: 10.21037/tlcr.2017.05.02. Review.

31.

Novel immunotherapy clinical trials in malignant pleural mesothelioma.

Tano ZE, Chintala NK, Li X, Adusumilli PS.

Ann Transl Med. 2017 Jun;5(11):245. doi: 10.21037/atm.2017.03.81.

32.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS.

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. Review.

33.

Competing risks analysis in the prognostic assessment of patients undergoing lung resection.

Eguchi T, Adusumilli PS.

J Thorac Dis. 2017 Apr;9(4):E395-E397. doi: 10.21037/jtd.2017.03.144. No abstract available.

34.

CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.

Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS.

Transl Res. 2017 Sep;187:1-10. doi: 10.1016/j.trsl.2017.04.004. Epub 2017 Apr 26. Review.

35.

Hot nodules and histologic features: The emerging story of stage IA lung adenocarcinoma.

Takahashi Y, Adusumilli PS.

J Thorac Cardiovasc Surg. 2017 Sep;154(3):1075-1076. doi: 10.1016/j.jtcvs.2017.04.014. Epub 2017 Apr 19. No abstract available.

PMID:
28495060
36.

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma.

Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D'Angelo SP, Bains MS, Bott M, Huang J, Park BJ, Rusch VW, Adusumilli PS, Tap WD, Singer S, Jones DR.

J Thorac Cardiovasc Surg. 2017 Jul;154(1):319-330.e1. doi: 10.1016/j.jtcvs.2017.02.061. Epub 2017 Mar 21.

37.

CAR T-cell therapy for pancreatic cancer.

DeSelm CJ, Tano ZE, Varghese AM, Adusumilli PS.

J Surg Oncol. 2017 Jul;116(1):63-74. doi: 10.1002/jso.24627. Epub 2017 Mar 27. Review.

38.

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.

Chen N, Morello A, Tano Z, Adusumilli PS.

Oncoimmunology. 2016 Dec 23;6(2):e1273302. doi: 10.1080/2162402X.2016.1273302. eCollection 2017.

39.

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Shaikh F, Zauderer MG, von Reibnitz D, Wu AJ, Yorke ED, Foster A, Shi W, Zhang Z, Adusumilli PS, Rosenzweig KE, Krug LM, Rusch VW, Rimner A.

J Thorac Oncol. 2017 Jun;12(6):993-1000. doi: 10.1016/j.jtho.2017.02.026. Epub 2017 Mar 21.

40.

Risk stratification for lung nodules: Size isn't everything.

Eguchi T, Adusumilli PS.

J Thorac Cardiovasc Surg. 2017 Jun;153(6):1557-1562. doi: 10.1016/j.jtcvs.2016.12.068. Epub 2017 Feb 16. No abstract available.

PMID:
28314535
41.

Reply to C.G. Rusthoven et al.

Eguchi T, Adusumilli PS.

J Clin Oncol. 2017 May 20;35(15):1751-1752. doi: 10.1200/JCO.2016.72.0029. Epub 2017 Feb 21. No abstract available.

PMID:
28221863
42.

Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis.

Eguchi T, Bains S, Lee MC, Tan KS, Hristov B, Buitrago DH, Bains MS, Downey RJ, Huang J, Isbell JM, Park BJ, Rusch VW, Jones DR, Adusumilli PS.

J Clin Oncol. 2017 Jan 20;35(3):281-290. doi: 10.1200/JCO.2016.69.0834. Epub 2016 Oct 31.

43.

Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy.

Yang HX, Woo KM, Sima CS, Bains MS, Adusumilli PS, Huang J, Finley DJ, Rizk NP, Rusch VW, Jones DR, Park BJ.

Ann Surg. 2017 Feb;265(2):431-437. doi: 10.1097/SLA.0000000000001708.

44.

Next frontiers in CAR T-cell therapy.

Brown CE, Adusumilli PS.

Mol Ther Oncolytics. 2016 Nov 30;3:16028. eCollection 2016. No abstract available.

45.

Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.

Leeman JE, Rimner A, Montecalvo J, Hsu M, Zhang Z, von Reibnitz D, Panchoo K, Yorke E, Adusumilli PS, Travis W, Wu AJ.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):138-145. doi: 10.1016/j.ijrobp.2016.09.037. Epub 2016 Sep 29.

46.

KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Kadota K, Sima CS, Arcila ME, Hedvat C, Kris MG, Jones DR, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2016 Dec;40(12):1579-1590.

47.

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma.

Lu S, Tan KS, Kadota K, Eguchi T, Bains S, Rekhtman N, Adusumilli PS, Travis WD.

J Thorac Oncol. 2017 Feb;12(2):223-234. doi: 10.1016/j.jtho.2016.09.129. Epub 2016 Sep 28.

48.

Attaining Proficiency in Robotic-Assisted Minimally Invasive Esophagectomy While Maximizing Safety During Procedure Development.

Sarkaria IS, Rizk NP, Grosser R, Goldman D, Finley DJ, Ghanie A, Sima CS, Bains MS, Adusumilli PS, Rusch VW, Jones DR.

Innovations (Phila). 2016 Jul-Aug;11(4):268-73. doi: 10.1097/IMI.0000000000000297.

49.

Surgical immune interventions for solid malignancies.

Zeltsman M, Mayor M, Jones DR, Adusumilli PS.

Am J Surg. 2016 Oct;212(4):682-690.e5. doi: 10.1016/j.amjsurg.2016.06.008. Epub 2016 Jul 18. Review.

50.

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.

J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.

Supplemental Content

Loading ...
Support Center